Last: | $2.35 |
---|---|
Change Percent: | -1.36% |
Open: | $2.23 |
Close: | $2.35 |
High: | $2.39 |
Low: | $2.22 |
Volume: | 358,056 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.35 | $2.23 | $2.35 | $2.39 | $2.22 | 358,056 | 07-05-2024 |
$2.2 | $2.24 | $2.2 | $2.26 | $2.185 | 167,198 | 07-04-2024 |
$2.2 | $2.24 | $2.2 | $2.26 | $2.185 | 167,198 | 07-03-2024 |
$2.24 | $2.35 | $2.24 | $2.35 | $2.23 | 183,771 | 07-02-2024 |
$2.37 | $2.39 | $2.37 | $2.43 | $2.31 | 238,271 | 07-01-2024 |
$2.35 | $2.44 | $2.35 | $2.44 | $2.31 | 1,248,159 | 06-28-2024 |
$2.43 | $2.31 | $2.43 | $2.45 | $2.25 | 484,431 | 06-27-2024 |
$2.29 | $2.54 | $2.29 | $2.56 | $2.28 | 440,145 | 06-26-2024 |
$2.53 | $2.72 | $2.53 | $2.72 | $2.52 | 251,218 | 06-25-2024 |
$2.73 | $2.66 | $2.73 | $2.825 | $2.64 | 278,605 | 06-24-2024 |
$2.64 | $2.55 | $2.64 | $2.6638 | $2.55 | 229,568 | 06-21-2024 |
$2.52 | $2.61 | $2.52 | $2.62 | $2.49 | 176,199 | 06-20-2024 |
$2.61 | $2.69 | $2.61 | $2.69 | $2.59 | 143,914 | 06-19-2024 |
$2.61 | $2.69 | $2.61 | $2.69 | $2.59 | 143,914 | 06-18-2024 |
$2.69 | $2.75 | $2.69 | $2.75 | $2.5601 | 304,041 | 06-17-2024 |
$2.81 | $2.73 | $2.81 | $2.87 | $2.69 | 194,133 | 06-14-2024 |
$2.76 | $2.79 | $2.76 | $2.82 | $2.735 | 128,237 | 06-13-2024 |
$2.79 | $2.92 | $2.79 | $3.06 | $2.77 | 149,527 | 06-12-2024 |
$2.82 | $2.79 | $2.82 | $2.89 | $2.67 | 143,088 | 06-11-2024 |
$2.78 | $2.85 | $2.78 | $2.86 | $2.75 | 465,259 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...